125 filings
Page 3 of 7
8-K
hyq7 doc4l
20 Jan 23
Departure of Directors or Certain Officers
8:03am
8-K
kb3fhnyn dwu
18 Jan 23
Entry into a Material Definitive Agreement
4:28pm
8-K
u1uk415xy27l
17 Jan 23
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
8:00am
8-K
16mbyuu4
12 Jan 23
Entry into a Material Definitive Agreement
5:00pm
8-K
86031alw
5 Jan 23
Other Events
9:30am
8-K
4j5jumapa
4 Jan 23
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
8:30am
8-K
d88zhpb65zvsj4
29 Dec 22
Entry into a Material Definitive Agreement
4:30pm
8-K
l3116y
29 Dec 22
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
8:30am
8-K
khrp6ub12klenkcb15s
22 Dec 22
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering
5:15pm
8-K
6j2zz n80zt
16 Dec 22
180 Life Sciences Corp. Announces 1-FOR 20 Reverse Stock Split As Part of Nasdaq Compliance Plan
9:00am
8-K
s48ed1h7i1ubd sa
30 Nov 22
Regulation FD Disclosure
5:00pm
8-K
nkkse51gcui5q2fh ckj
15 Nov 22
Adalimumab Found To Be a Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
4:15pm
8-K
tudmdfmkns42ndz76ae
4 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
j0blntijv
26 Sep 22
180 Life Sciences Issues Letter to Stockholders
8:30am
8-K
04pq1pt gfi
22 Aug 22
Regulation FD Disclosure
8:31am
8-K
ihuk v54khwe
27 Jul 22
Regulation FD Disclosure
8:35am
8-K
1yh090uud3
19 Jul 22
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering
4:11pm
8-K
0epq37io
22 Jun 22
180 Life Sciences Corp. Issues Letter to Stockholders
4:15pm
8-K
34q5d
14 Jun 22
Departure of Directors or Certain Officers
4:15pm
8-K
mrgy2rdko7kckpl
26 May 22
Departure of Directors or Certain Officers
8:45pm